Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fidaxomicin (Tiacumicin B) 是一种大环RNA 聚合酶抑制剂,具有窄谱活性。它选择性地根除致病性艰难梭菌,对构成正常健康肠道菌群的多种细菌影响很小。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 mg | ¥ 282 | 现货 | ||
25 mg | ¥ 455 | 现货 | ||
50 mg | ¥ 663 | 现货 | ||
100 mg | ¥ 989 | 现货 | ||
200 mg | ¥ 1,490 | 现货 | ||
500 mg | ¥ 2,760 | 现货 | ||
1 g | ¥ 3,970 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 349 | 现货 |
产品描述 | Fidaxomicin (Tiacumicin B) is a semisynthetic macrolide antibiotic used to treat Clostridium difficile-associated diarrhea in adults. Fidaxomicin has minimal systemic absorption and has not been linked to serum enzyme elevations during therapy or to instances of clinically apparent, acute liver injury. |
体外活性 | Fidaxomicin acts as a RNA polymerase inhibitor by binding to the DNA template–RNA polymerase (RNAP) complex prior to the formation of the open RNAP-DNA complex in which transcription is initiated. Therefore it will inhibit protein synthesis. As a result, apoptosis is triggered in susceptible organisms such as C. difficile. [1] |
体内活性 | The minimum inhibitory concentration for 90% of organisms for fidaxomicin against C. difficile is 0.9978 to 2 μg/mL. Fidaxomicin is not systemically absorbed as shown by a plasma concentrations below the lower limit of quantification after single-dose or multiple-dose. In contrast, fecal concentrations of fidaxomicin are much higher and are concentration-dependent. Cmax = 2 hours; Tmax = 5.2 ng/mL; AUC = 14 ng?hr/mL. Fidaxomicin is hydrolyzed by gastric acid or intestinal microsomes into a less active metabolite (OP-1118). The cytochrome enzyme system are not involved in the metabolism of fidaxomicin. [1] |
别名 | 非达米星, Tiacumicin B, OPT-80, Clostomicin B1, PAR-101 |
分子量 | 1058.04 |
分子式 | C52H74Cl2O18 |
CAS No. | 873857-62-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 93 mg/mL (87.9 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 0.9451 mL | 4.7257 mL | 9.4514 mL | 23.6286 mL |
5 mM | 0.189 mL | 0.9451 mL | 1.8903 mL | 4.7257 mL | |
10 mM | 0.0945 mL | 0.4726 mL | 0.9451 mL | 2.3629 mL | |
20 mM | 0.0473 mL | 0.2363 mL | 0.4726 mL | 1.1814 mL | |
50 mM | 0.0189 mL | 0.0945 mL | 0.189 mL | 0.4726 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Fidaxomicin 873857-62-6 Apoptosis Cell Cycle/Checkpoint DNA Damage/DNA Repair Microbiology/Virology Antibacterial Antibiotic DNA/RNA Synthesis CDAD Clostridium difficile PAR101 difimicin 非达米星 Inhibitor orally active OPT 80 Tiacumicin B PAR 101 CDI inhibit OPT-80 Bacterial RNA polymerase OPT80 Clostomicin B1 PAR-101 inhibitor